Experts’ clinical trials reportedly show outstanding results that the drug for a type of incurable breast cancer delays the disease getting worse.
The study found out that Olaparib (Lynparza), can give women living with BRCA-mutated advanced breast cancer a significant extra time before their disease progresses.
Presented at the American Society of Clinical Oncology (Asco), in Chicago, the trial compared olaparib with chemotherapy for patients with HER2-negative BRCA-mutation advanced breast cancer.
At a follow-up of about 14 months, patients who received olaparib had a 42% lower chance of cancer progression than those who received chemotherapy.
Olaparib – which is one of a new class of drugs known as PARP inhibitors – was developed after research by UK scientists at the Breast Cancer Now Research Centre at the Institute of Cancer Research in London.
The drug works by blocking a DNA repair protein known as PARP, causing breast cancer cells to d*e.
Baroness Delyth Morgan, chief executive of Breast Cancer Now, said: “Olaparib could now become the first biologically targeted drug for a group of patients with incurable and aggressive breast cancer who currently have few treatment options.”
“That it can offer around three extra months before the disease progresses compared to chemotherapy – and a better quality of life during that time – will be invaluable to so many women and their families,” she added.
It is estimated that around 1,500 women a year with the difficult-to-treat cancer could benefit from the drug.